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Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S94(AML 76%, ALL-CR1100%, MDS 67%, ALL-CR2-3 59%), with an
estimated NRM@1year of 9+/-4% and relapse@1year of 21+/-
7%. Other endpoints: Probability of neutrophil engraftment
100% @day60 and thrombocyte engraftment (50x10e9/L) of
84+/-6% @day 180, only 1 graft failure (1.5%: MUD donor.
Successfully re-grafted with CB) was noted. Toxicity end-
points: aGvHD 2-4 @day 180 was 32+/-6% (grade 3-4: 14+-
4%), extensive cGvHD@1year 8+-6%, non-infectious lung-
injury @ 2 years 12+-4% and no VOD (0%) was noted.
Conclusion: The preliminary results of this TBI-free condi-
tioning regimen (CloFluBu) in myeloid- and lymphoblastic
malignancies showed limited toxicity and encouraging LFS
given the high risk group of patients. A longer follow-up and
a larger cohort is needed to draw ﬁrm conclusions with
regards to the anti-leukemic effect and late effects.Figure 1. Overall survival (OS) and event-free survival (EFS).91
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Fanconi anemia(FA) is a rare genetic disorder characterizedby
congenital defects, bone marrow failure and cancer predis-
position. Over the past decade, survival after HSCT has greatly
improved and the use of protocols without radiation are
preferred in order to decrease late complications related to
the development of head and neck cancer. In this study we
analyzed 103 patients(pts) with FA who were transplanted
between 2003 and 2014. The median age at HSCT was
9ys(range: 3-23ys). All pts were transplanted in marrow
failure and received bone marrow from matched siblings
(MSD) (n¼49) or Alternative donors (AD) (n¼54). This latter
group included 12 other related donors(ORD) and 42 unre-
lated donors(URD). Preparatory regimen with Cyclophos-
phamide 60mg/kg(CY60) was given to all pts with MSD or
ORDwhile ptswith URD received CY60 + Fludarabine 125mg/
m2 + rabbit ATG 5mg/kg. All pts received GVHD prophylaxis
with cyclosporine and methotrexate. Three pts died before
D+28 andwerenot evaluable for engraftment (MSD: 2 pts and
URD: 1 pt). One patient (MSD) developed primary graft fail-
ure, received a 2nd transplant without success andwas ﬁnally
rescued after a 3rd transplantwith a haploidentical donor. She
is alive andwell 3ys after HSCT. Ninety-nine pts engrafted but
5 pts developed late graft failure (MSD¼2pts; ORD¼1pt;
URD¼1pt) between 50 and 742 days after transplant (M: 84
days). Four out of these 5 pts are alive andwell with full donor
chimerism after a 2nd or 3rd HSCT. At last follow-up, the ma-
jority of pts transplanted from AD had full donor chimerism
(96%) while approximately 50% of pts with MSD donors had
mixed chimerism.Mucositis grade II-III occurred in 70%of pts.
Viral infectionsweremore frequentwhenADwereused(60%)
compared toMSD(28%). Hemorrhagic cystitis occurred in 22%
of AD transplants and it was uncommon after MSD trans-
plants (only1 pt). After AD transplantation, acuteGVHDgradeII-IV occurred in 12/53 evaluable pts and any Chronic GVHD
occurred in 21/38 evaluable pts.MSDhad a lower incidence of
acute GVHD (3/47 evaluable pts) while Chronic GVHD
occurred in 14/47 evaluable pts. Ninety-one pts are alive be-
tween 7 months and 10 years (M: 5 yrs) with an overall sur-
vival of 87% at 5 years. There was no difference in survival
according to the type of donor MSD (92%), ORD (92%) and
URD(83%). Patients without Acute GVHD had an overall sur-
vival of 98% compared to 58% with acute GVHD (p:0.001).
Twelve pts died between 3 and 1855 days after HSCT(M:65
days). Acute or chronic GVHDwere the major causes of death
(n¼8) followed by infections (n¼3) and central nervous sys-
tem bleeding (n¼1).
Conclusions: HSCT for FA has improved dramatically during
the past decade. In this study, the use of non-irradiation
protocols was associated with an excellent survival, suc-
cessful engraftment and very low mortality rate.
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Background: Cord blood transplant (CBT) recipients have
delayed hematopoietic recovery compared to recipients of
other stem cell sources following allogeneic transplant. Pro-
longed neutrophil (ANC) recovery, in particular, places these
patients at risk of protracted mucositis, extended hospitali-
zation and increased risk of infection-related morbidity and
mortality. To mitigate these risks, we have developed a
methodology for generating increased absolute numbers of
cord blood (CB) hematopoietic stem/progenitor cells (HSPC)
by culture of the CB HSPC in the presence of Notch ligand,
cryopreserving theﬁnal harvested product, and subsequently
administering the product as an adjunct cellular therapy to
patients receiving CBT. This has resulted in signiﬁcantly
decreased time to neutrophil recovery following CBT1. Here
we evaluatedwhether administration of these cells impacted
duration of hospitalization, use of opiate pain medications,
and requirement for total parenteral nutrition (TPN) or in-
fectious outcomes during initial hospitalization for CBT.
Figure 1. Overall survival (OS) and event-free survival (EFS).
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S95Methods: Pediatric patients (<21 years old, n¼34) on a
research protocol between 4/2006 and 6/2014 receiving
myeloablative conditioning (FLU/CY/13.2 Gy TBI) with or
without expanded CB HSPC (fresh or cryopreserved) were
included. Duration of initial hospitalization, use of opiate
pain medications (by continuous infusion or PCA), and use of
TPN were determined for each patient. All blood stream in-
fections occurring during initial hospitalization were also
recorded. Statistical comparisons between groups were
made with two-tailed, unpaired t-tests.
Results: 11 patients received expanded CBHSPC in addition to
1-2 unmanipulated CB units while a concurrent cohort of 23
patients received the same conditioning regimen without
expanded cell infusion. The mean time to neutrophil count of
500/mlwas16.5v.22.1days inpatients receivingexpandedcells
or not, respectively (p¼0.026). The mean duration of initial
hospitalization was 43.2 v. 55.6 days (p¼0.05) (Fig. 1), mean
duration for continuous opiate medications 9.7 v. 18.1 days
(p¼0.07), and mean time receiving TPN was 20.7 v. 30.1 days
(p¼0.06) (Fig. 2). Although not statistically signiﬁcant,
bacterial blood stream infections were identiﬁed during their
initial hospitalization in 3 patients receiving expanded CB
HSPC compared to 10 in the standard treatment group.
Conclusions: In addition to reduce time to ANC recovery,
these results suggest that administration of expanded CB
HSPC may signiﬁcantly reduce initial hospitalization and
may also reduce utilization of pain medications and nutri-
tional support in the pediatric population receiving CBT.
Thus, this cellular therapy has the potential to decrease the
risk of morbidity and mortality post-CBT by reducing
regimen related toxicities that directly result from delayed
hematopoietic recovery.93
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HCT for children with severe sickle cell disease have
improved with disease-free survival approaching 95%. As
outcomes have improved, interest in extending HCT to less
severely affected children has increased. However, there re-
mains little published experience in these patients. We
describe the largest multi-institutional retrospective review
of MSD HCT for patients with less severe SCD.
Methods: Patients who received MSD HCT at three centers
(Children’s National Medical Center, Children’s Healthcare of
Atlanta, and Columbia University Medical Center) between
January 2004eJune 2014 were eligible for inclusion in the
analysis. Thosewith severe complications, such as stroke and
recurrent acute chest syndrome, were excluded, using eligi-
bility criteria from a recently completed trial for severe SCD
(clinicaltrials.gov, NCT00968162).
Results: 25 patients (M/F: 13/12) met eligibility. 22 had HbSS
and 3 HbSC. The median age was 5.3 years (1-18.3). 8 patients
had no acute SCD related-complications. The most frequent
complication was vaso-occlusive pain 14/25 (56%) with a life-
timemedian of 1 crisis. 7 patients had splenic sequestration as
the only acute complication. Twenty-four received myeloa-
blative conditioning; 19 received BM, 3 cord blood (CB) and 3
BM + CB. Donor engraftment was achieved in all cases. Mean
peripheral whole blood or myeloid donor chimerismwas 94%
and 89%, at day +100 and +365 respectively. No patients suf-
fered severe regimen-related toxicities and none experienced
seizures, encephalopathy or other neurologic complications.
One patient developed acute GVHD (grade III), which respon-
ded to therapy. None developed chronic GVHD. Of the 17 pa-
tients who are a year or more from transplant, all are off
immune suppression. With a median follow-up of 23 months
(5-130 months) all patients are alive and free of SCD.
Conclusions: HLA MSD HCT for children with less severe
sickle cell appears to be highly effective. Given that nearly all
patients with SCD, regardless of their disease course during
childhood, will suffer serious morbidity as adults and have a
markedly shortened life expectancy, our experience suggests
HCT is appropriate for children with less severe disease.
Prospective studies involving these patients are needed.94
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